Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects
Clinical trial NCT02508753 · COMPLETED
Trial details
- NCT number
- NCT02508753
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-01
- Primary completion
- 2010-07-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.